Rates of Head, Neck Melanoma Up in North American Youth
Risk for head, neck melanoma higher for male sex, older age, non-Hispanic white ethnicity
Skin Cancer News
SKIN CANCER ADVISOR
Skin Cancer News
How Do Melanoma Survivors and Their Partners Feel About Skin Self-Examination?
This study sought to determine gender differences regarding melanoma survivors’ perceptions of partner support and comfort in performing skin self-examinations.
Indoor Tanning May Up Risk for Squamous Cell Carcinoma
Dose-response association found between indoor tanning and SCC risk among women.
Promising Results for Targeted Methylation Sequencing in the Detection of Multiple Types of Cancer
The precision of the targeted methylation sequencing assay for localizing the cancer tissue of origin was reported to be 89%.
Longer Duration of Steroids May Affect Outcomes During Anti-PD-1 Treatment
The use of steroids for the treatment of immune-related adverse events may have survival consequences.
Real-World Data Support Gut Microbiota as an Independent Driver of Response to ICIs in Lung Cancer, Melanoma
Antibiotic therapy administered prior to treatment with ICIs was negatively associated with OS across tumor types, as well as tumor response, the researchers noted.
Treatment-Free Survival Emerges as Novel End Point for Immunotherapy Trials
Treatment-free survival could help capture additional perspective about the patient experience during immune checkpoint inhibitor therapy, a study concluded.
2001 to 2016 Saw Large Increase in Mohs Surgery for Melanoma
Regional variation considerable, with more than threefold variation between regions with highest, lowest use.
TKI Combination vs Monotherapy for Advanced Melanoma and the Risk for CV Adverse Events
A meta-analysis sought to determine if survival is improved with dual targeting of the MAPK pathway with BRAF and MEK inhibitors vs BRAF inhibition alone in patients with advanced melanoma.
Rozlytrek, a Tumor Agnostic Therapy, Receives FDA Approval
The Food and Drug Administration (FDA) has granted accelerated approval to Rozlytrek (entrectinib; Genentech).
Bempegaldesleukin Combo Regimen Gets Breakthrough Status for Untreated Advanced Melanoma
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to bempegaldesleukin (NKTR-214; Nektar Therapeutics and Bristol-Myers Squibb) in combination with nivolumab (Opdivo; Bristol-Myers Squibb) for the treatment of patients with previously untreated unresectable or metastatic melanoma.
Dietary Vitamin A Intake Tied to Reduced Risk for Squamous Cell Carcinoma
Cutaneous SCC risk reduced for highest versus lowest quintile of vitamin A, retinol, some carotenoids.
Determining Risk Factors for Recurrence of Primary Localized Cutaneous Melanoma
Researchers sought to determine the risk of disease recurrence in patients with localized melanoma at high risk of disease metastasis.
Time Between Initial Surgery and First Distant Recurrence Not Predictive of Response to Systemic Therapy in Metastatic Melanoma
With the exception of those enrolled in a clinical trial, all patients in this study received systemic monotherapy as first-line treatment of metastatic melanoma.
Calculated Tumor Area Has Prognostic Value for Melanoma
Calculated tumor area is a novel, microscopic feature and a two-dimensional surrogatefor tumor size.
Machine Versus Physician: Assigning Diagnoses to Pigmented Skin Lesions
Approximately one half of all biopsied/excised lesions from patients who have sun-damaged skin are nonmelanocytic.
Carbamazepine and Lamotrigine Associated With Increased Risk for SCC
A comparison of AEDs finds that while most were not associated with skin cancer, carbamazepine and lamotrigine were associated with squamous cell carcinoma.
The Role of Metastasectomy for Melanoma Reexamined in the Modern Era
In the modern era of therapeutic agents, metastasectomy was still associated with improved survival outcomes for patients with stage IV melanoma.
Adjuvant Whole-Brain Radiotherapy Not Recommended for Melanoma Brain Metastases
Secondary end points were not significantly different between the 2 groups, including overall survival.
How to Treat Melanoma After Checkpoint Inhibitors Fail
The combination of ipilimumab and nivolumab resulted in a higher rate of objective remissions compared with ipilimumab alone.
Want to read more?
Please login or register first to view this content.
Next post in Skin Cancer
